Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P23467

UPID:
PTPRB_HUMAN

ALTERNATIVE NAMES:
Vascular endothelial protein tyrosine phosphatase

ALTERNATIVE UPACC:
P23467; B7ZKS8; B7ZKT0; C9JX87; F5H3G6; Q14D85; Q3MIV7

BACKGROUND:
Receptor-type tyrosine-protein phosphatase beta, known alternatively as Vascular endothelial protein tyrosine phosphatase, is crucial for the maintenance and remodeling of blood vessels. It ensures the dephosphorylation of TEK/TIE2, CDH5/VE-cadherin, and KDR/VEGFR-2, thereby regulating angiopoietin-TIE2 signaling in endothelial cells. This protein acts as a negative regulator of TIE2, affecting endothelial cell proliferation and blood vessel remodeling, which is vital for embryonic development and perinatal growth.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Receptor-type tyrosine-protein phosphatase beta offers a promising avenue for developing novel therapeutic strategies. Given its critical role in endothelial cell function and blood vessel remodeling, targeting this protein could lead to breakthroughs in treating vascular disorders and enhancing angiogenesis.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.